Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16987222 | 1.00 | TARS1 (0.38) | TARS1SLC29A1ADORA1LMNATP53 | |
| SCHEMBL28564130 | 1.00 | TARS1 (0.38) | TARS1SLC29A1ADORA1LMNATP53 | |
| SCHEMBL29089525 | 0.88 | TARS1 (0.39) | TARS1SLC29A1ADORA1 | |
| SCHEMBL28475028 | 0.87 | SLC29A1 (0.46) | SLC29A1ADORA1LMNATP53ALOX15 | |
| SCHEMBL26090156 | 0.86 | HTR2B (0.35) | TARS1ADORA1 | |
| SCHEMBL29413061 | 0.86 | HTR2B (0.35) | TARS1ADORA1 | |
| SCHEMBL28300819 | 0.85 | ADORA3 (0.35) | TARS1ADORA1 | |
| SCHEMBL30950292 | 0.85 | TARS1 (0.37) | TARS1SLC29A1ADORA1 | |
| SCHEMBL31675871 | 0.84 | AHCY (0.41) | ADORA1 | |
| SCHEMBL17627818 | 0.84 | RXFP1 (0.39) | SLC29A1ADORA1LMNATP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119421870-A | Lipid compound and application thereof | 传信生物医药(苏州)有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119384273-A | Organ-specific delivery compositions for nucleic acids | 传信生物医药(苏州)有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119355174-A | TRNA modified molecular marker for acute myeloid leukemia diagnosis and application | 广州市金域转化医学研究院有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118613500-A | Modified mRNA treatment | 沙塔克实验室有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-118475599-A | Chimeric proteins for the treatment of skin inflammation | 沙塔克实验室有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-117500823-A | Chimeric proteins in autoimmunity | 沙塔克实验室有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117413065-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-111744019-B | Mannose-based mRNA targeted delivery system and application thereof | 深圳瑞吉生物科技有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| CN-114929244-A | Mannose-based mRNA targeted delivery system and application thereof | 深圳市瑞吉生物科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114502204-A | RNA combinations and compositions with reduced immunostimulatory properties | 库尔维科公司 | 2022-05-13 | — | — | CN | claimed |
| CN-122074087-A | Reverse transcription mediated gene editing system and use thereof | 阿伯生物技术公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-122070366-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-14 | — | — | US | disclosed |
| CN-114502204-A | RNA combinations and compositions with reduced immunostimulatory properties | 库尔维科公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114404581-A | Cancer vaccine | 摩登纳特斯有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114317612-A | RNA preparations comprising purified modified RNA for reprogramming cells | 宾夕法尼亚州大学信托人 | 2022-04-12 | — | — | CN | disclosed |
| CN-107690480-B | Evaluation of CAS9 molecule/guide RNA molecule complexes | 爱迪塔斯医药公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-107406854-B | RNA-guided eradication of human JC virus and other polyomaviruses | 英联邦高等教育系统天普大学 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | HLA-B, ADA, HLA-A | TARS1 3666/4885SLC29A1 1153/4885ADORA1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.